奥泰生物(688606) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥172,091,295.89, a decrease of 39.94% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥30,383,843.98, down 47.47% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2023 was ¥26,459,823.33, a decline of 28.28% compared to the previous year[5] - Total operating revenue for the first three quarters of 2023 was CNY 559,938,588.88, a significant decrease from CNY 3,010,066,325.12 in the same period of 2022, representing a decline of approximately 81.4%[20] - Net profit for the third quarter of 2023 was CNY 101,246,320.67, compared to CNY 1,360,728,055.79 in the same quarter of 2022, reflecting a decrease of approximately 92.6%[22] - Total equity attributable to shareholders was CNY 3,746,472,678.69, compared to CNY 4,166,522,369.83 in the previous year, indicating a decline of approximately 10.1%[20] - The company reported a total comprehensive income of CNY 105,130,220.85 for the third quarter of 2023, significantly lower than CNY 1,389,507,937.47 in the same quarter of 2022[23] Research and Development - The total R&D expenditure for Q3 2023 was ¥23,814,423.26, a significant decrease of 59.94% year-on-year[6] - The company’s research and development expenses for the first three quarters of 2023 were CNY 89,692,899.23, down from CNY 159,378,738.69 in the same period of 2022, a reduction of approximately 43.6%[20] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,045,547,457.63, a decrease of 13.92% from the end of the previous year[6] - As of September 30, 2023, the company's total assets amounted to approximately ¥4.05 billion, a decrease from ¥4.70 billion at the end of 2022, reflecting a decline of about 13.8%[17] - Total liabilities as of the end of the third quarter of 2023 amounted to CNY 294,791,478.34, down from CNY 528,800,790.03 at the end of the same period in 2022, a decrease of about 44.3%[20] Cash Flow - The company reported a cash flow from operating activities net amount of -¥84,029,870.64 for the year-to-date, reflecting a decline of 108.35%[6] - In the first three quarters of 2023, the cash inflow from operating activities totaled approximately ¥559.87 million, a decrease of 82.27% compared to ¥3.16 billion in the same period of 2022[25] - The net cash flow from operating activities for the third quarter of 2023 was -¥84.03 million, contrasting sharply with a positive cash flow of ¥1.01 billion in Q3 2022[26] - The company reported a net cash decrease of approximately ¥576.62 million in Q3 2023, compared to a decrease of ¥272.79 million in Q3 2022, indicating a worsening cash position[26] Shareholder Information - The company reported a total of 7.596 million common shareholders as of the end of the reporting period[14] - The top ten shareholders collectively control approximately 52.76% of the company, with the largest shareholder holding 23.33%[16] - The company has a repurchase account holding 1,124,043 shares, representing 1.42% of total shares, which is not included in the top ten shareholders[16] Market Outlook - The company anticipates continued challenges in revenue due to the significant decline in sales of COVID antigen testing products[12] - The revenue from non-COVID testing products increased by 26.01% year-on-year, excluding the impact of COVID-related business[11] - The company plans to expand its market presence, but further details on specific strategies were not provided[15] - There were no significant mergers or acquisitions reported during the quarter[15] Cash Management - The company's cash and cash equivalents decreased to approximately ¥1.41 billion from ¥1.98 billion, representing a decline of about 29.0%[17] - The total current assets decreased to approximately ¥3.14 billion, down from ¥4.19 billion, indicating a reduction of about 25.1%[18] - The company's accounts receivable decreased to approximately ¥123.49 million from ¥138.66 million, a decline of about 10.9%[18] - The cash inflow from investment activities in the first three quarters of 2023 was approximately ¥1.42 billion, an increase of 5.36% from ¥1.35 billion in the same period of 2022[26] - The cash paid for purchasing goods and services in the first three quarters of 2023 was approximately ¥336.71 million, down 77.73% from ¥1.51 billion in the same period of 2022[25] - The cash received from tax refunds in the first three quarters of 2023 was approximately ¥20.05 million, a decrease of 89.51% compared to ¥191.39 million in the same period of 2022[25]